Nicole Peters Email

Head FP&A . Inozyme Pharma

Current Roles

Employees:
62
Revenue:
$9.8M
About
We are a biopharmaceutical company specializing in the development of novel therapeutics to treat rare metabolic diseases. Our lead product candidate is INZ-701, an enzyme replacement therapy (ERT) in the early stages of clinical development for the potential treatment of patients with a variety of calcification disorders linked primarily to mutations in the ENPP1 and ABCC6 genes, or ENPP1 Deficiency and ABCC6 Deficiency respectively. We have demonstrated proof of concept with INZ-701 in both GACI and ARHR2 two phenotypes of ENPP1 Deficiency.
Inozyme Pharma Address
321 Summer Street
Boston, MA
United States
Inozyme Pharma Email

#1 Startup Dataset

Growth rates, revenue data, direct competitors and contact details.